Osteoporosis is the silent thief, and an osteoporotic fracture can be thought of as a bone attack. Access the microsite to enhance your knowledge of the impact and prevalence of osteoporosis, learn to recognize risk factors for fragility fractures and review the latest treatment guidelines. Two engaging patient cases developed with what if scenarios will optimize your learning.

Learning objectives

  • Recognize risk factors for fragility fractures
  • Identify patients at high risk for fragility fractures in the post-pandemic setting
  • Understand different treatment strategies for the prevention of fragility fractures in patients with osteoporosis
Please register or login in order to access this content

Scientific Planning Committee

Faculty Disclosure

Faculty Disclosures

Vivien Brown (MDCM, CCFP, FCFP, NCMP)
Assistant Professor, Department of Family & Community Medicine
University of Toronto
Toronto, ON

Dr. Brown received honoraria and had consulting roles, as well as served on advisory boards and as a speaker for MD Briefcase, Meducom, The Rounds, Antibody, STA Communications, Immunize Canada, Women’s Brain Health Initiative, Amgen, Allergan, Bayer, Biosyent, GSK Merck, Novo Nordisk, Novartis, Pfizer, Sunovion, and Searchlight.

Jeffrey Habert (MD, CCFP, FCFP)
Assistant Professor, Department of Family & Community Medicine
University of Toronto
Toronto, ON

Dr. Habert received honoraria and had consulting roles, as well as served on advisory boards and as a speaker for CPD Network Association, Allergan, Alliance, Academy, Amgen, Antibody, AstraZeneca, BMS, Bayer, Boehringer Ingelheim, Brandaide, Bridge, CHRC, CTA, CCRN, Eisai, Eli Lilly, Four Health Comm, Janssen, Lundbeck, liV, Master Clinician, Meducom, MedPlan, MD Briefcase, Novartis, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Servier, and STA Communications.

Algis Jovaisas (MD, FRCPC)
Adjunct Professor of Medicine, Department of Medicine
University of Ottawa
Ottawa, ON

Dr. Jovaisas received research funding, honoraria, as well as served on advisory boards and as a speaker, and had consulting roles for Amgen, Pfizer, Novartis, Sandoz, Eli Lilly, MSD, Gilead, and AbbVie.

 

Daniel Ngui (BScPT, MD, FCFP)
Clinical Professor, Department of Family Medicine
University of British Columbia
Vancouver, BC

Dr. Ngui received research funding, honoraria, as well as served on advisory boards, consult meetings and as a speaker, and had consulting roles for Amgen, AstraZeneca, BMS, BI, Lilly, Novo Nordisk, Simple Trial, Amgen 20170191 trial, IHE eCare CV Risk, CHRC EMR Registry Trials: AF OAC, Advantage CV, Advantage OP, and Pioneer REAL.

This non-accredited learning activity was developed by the CPD Network Association, a not-for-profit physician organization, in concert with the scientific planning committee members, and is based on current clinical practice guidelines or expert consensus. The program is for healthcare professionals only. Financial support was provided by Amgen Canada.

cpdisup